NASDAQ:GHDX - Genomic Health Stock Price, News & Analysis

$73.86
-0.36 (-0.49 %)
(As of 08/20/2019 04:00 PM ET)
Today's Range
$73.76
Now: $73.86
$74.56
50-Day Range
$55.81
MA: $65.35
$74.67
52-Week Range
$50.77
Now: $73.86
$92.18
Volume331,461 shs
Average Volume576,345 shs
Market Capitalization$2.75 billion
P/E Ratio70.34
Dividend YieldN/A
Beta1.06
Genomic Health, Inc, a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions. Read More…

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:GHDX
CUSIP37244C10
Phone650-556-9300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$394.11 million
Cash Flow$1.4345 per share
Book Value$7.48 per share

Profitability

Net Income$25.68 million

Miscellaneous

Employees829
Market Cap$2.75 billion
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable

Receive GHDX News and Ratings via Email

Sign-up to receive the latest news and ratings for GHDX and its competitors with MarketBeat's FREE daily newsletter.


Genomic Health (NASDAQ:GHDX) Frequently Asked Questions

What is Genomic Health's stock symbol?

Genomic Health trades on the NASDAQ under the ticker symbol "GHDX."

How were Genomic Health's earnings last quarter?

Genomic Health, Inc. (NASDAQ:GHDX) issued its earnings results on Monday, July, 29th. The medical research company reported $0.42 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.35 by $0.07. The medical research company earned $114.14 million during the quarter, compared to the consensus estimate of $110.78 million. Genomic Health had a return on equity of 19.51% and a net margin of 11.69%. The company's revenue was up 19.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.23 earnings per share. View Genomic Health's Earnings History.

When is Genomic Health's next earnings date?

Genomic Health is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for Genomic Health.

What guidance has Genomic Health issued on next quarter's earnings?

Genomic Health updated its FY19 earnings guidance on Monday, July, 29th. The company provided EPS guidance of $1.44-1.54 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.44. The company issued revenue guidance of $448-452 million, compared to the consensus revenue estimate of $445.06 million.

What price target have analysts set for GHDX?

9 Wall Street analysts have issued 1-year price targets for Genomic Health's shares. Their forecasts range from $55.00 to $72.00. On average, they expect Genomic Health's share price to reach $68.6667 in the next twelve months. This suggests that the stock has a possible downside of 7.0%. View Analyst Price Targets for Genomic Health.

What is the consensus analysts' recommendation for Genomic Health?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genomic Health in the last year. There are currently 9 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Genomic Health.

What are Wall Street analysts saying about Genomic Health stock?

Here are some recent quotes from research analysts about Genomic Health stock:
  • 1. According to Zacks Investment Research, "Over the past year, Genomic Health has been outperforming its industry. The company is registering robust top-line growth banking on solid performance in the United States and internationally. In the last-reported quarter, breast cancer revenues were strong driven by increased Oncotype DX Breast Recurrence Score test usage globally which is amplifying on favorable results from the landmark TAILORx trial. Within the prostate cancer space, the company is seeing robust improvement in volume as the Oncotype DX GPS test consistently leads the market in low- and intermediate-risk prostate cancer test adoption. However, the company’s sole reliance on the Breast Oncotype DX test is a concern. Moreover, the company continues to face fierce competition for Oncotype DX tests." (7/31/2019)
  • 2. Canaccord Genuity analysts commented, "We are also lowering our price target from $77 to the deal price of $72. Our prior $77 PT used a 6.7x multiple on our 2021 revenue estimate of $540M. We note that our peer group (as of today) is trading at 6.7x our 2020 revenue estimates." (7/30/2019)

Has Genomic Health been receiving favorable news coverage?

Media headlines about GHDX stock have been trending positive this week, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Genomic Health earned a media sentiment score of 2.5 on InfoTrie's scale. They also assigned media stories about the medical research company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the stock's share price in the next few days. View News Stories for Genomic Health.

Who are some of Genomic Health's key competitors?

What other stocks do shareholders of Genomic Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Genomic Health investors own include NVIDIA (NVDA), Illumina (ILMN), Ionis Pharmaceuticals (IONS), Revance Therapeutics (RVNC), Vertex Pharmaceuticals (VRTX), Exelixis (EXEL), GW Pharmaceuticals PLC- (GWPH), Horizon Therapeutics (HZNP), Incyte (INCY) and Intuitive Surgical (ISRG).

Who are Genomic Health's key executives?

Genomic Health's management team includes the folowing people:
  • Ms. Kimberly J. Popovits, Chairman, CEO & Pres (Age 60)
  • Dr. Steven Shak, Co-Founder & Chief Scientific Officer (Age 68)
  • Mr. G. Bradley Cole, Chief Financial Officer (Age 63)
  • Dr. Frederic G. Pla, Chief Operating Officer (Age 60)
  • Mr. James J. Vaughn, Chief U.S. Commercial Officer (Age 56)

Who are Genomic Health's major shareholders?

Genomic Health's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (7.58%), Renaissance Technologies LLC (7.55%), BlackRock Inc. (6.85%), Acadian Asset Management LLC (2.80%), Man Group plc (2.26%) and Invesco Ltd. (1.84%). Company insiders that own Genomic Health stock include Bros Advisors Lp Baker, Fred E Cohen, Frederic Pla, G Bradley Cole, Henry J Fuchs, James J Vaughn, Jason W Radford, Kim Mceachron, Kimberly J Popovits, Laura Leber, Phillip G Febbo and Steven Shak. View Institutional Ownership Trends for Genomic Health.

Which institutional investors are selling Genomic Health stock?

GHDX stock was sold by a variety of institutional investors in the last quarter, including Robeco Institutional Asset Management B.V., Prudential Financial Inc., Bogle Investment Management L P DE, JPMorgan Chase & Co., AXA, Jacobs Levy Equity Management Inc., Bank of America Corp DE and Copper Rock Capital Partners LLC. Company insiders that have sold Genomic Health company stock in the last year include Bros Advisors Lp Baker, Fred E Cohen, Frederic Pla, G Bradley Cole, Henry J Fuchs, James J Vaughn, Jason W Radford, Kim Mceachron, Kimberly J Popovits, Laura Leber and Steven Shak. View Insider Buying and Selling for Genomic Health.

Which institutional investors are buying Genomic Health stock?

GHDX stock was bought by a variety of institutional investors in the last quarter, including Invesco Ltd., Renaissance Technologies LLC, Nuveen Asset Management LLC, Vanguard Group Inc., Man Group plc, Acadian Asset Management LLC, AMI Asset Management Corp and BlackRock Inc.. View Insider Buying and Selling for Genomic Health.

How do I buy shares of Genomic Health?

Shares of GHDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Genomic Health's stock price today?

One share of GHDX stock can currently be purchased for approximately $73.86.

How big of a company is Genomic Health?

Genomic Health has a market capitalization of $2.75 billion and generates $394.11 million in revenue each year. The medical research company earns $25.68 million in net income (profit) each year or $1.05 on an earnings per share basis. Genomic Health employs 829 workers across the globe.View Additional Information About Genomic Health.

What is Genomic Health's official website?

The official website for Genomic Health is http://www.genomichealth.com/.

How can I contact Genomic Health?

Genomic Health's mailing address is 301 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The medical research company can be reached via phone at 650-556-9300 or via email at [email protected]


MarketBeat Community Rating for Genomic Health (NASDAQ GHDX)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  309 (Vote Outperform)
Underperform Votes:  359 (Vote Underperform)
Total Votes:  668
MarketBeat's community ratings are surveys of what our community members think about Genomic Health and other stocks. Vote "Outperform" if you believe GHDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GHDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel